Ascendis Pharma (ASND) Stock Overview

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

ASND Stock Information

Symbol

ASND

Address

Tuborg Boulevard 12Hellerup, 2900Denmark

Founded

Trading hours

9:30 AM - 4:00 PM ET

Website

https://ascendispharma.com

Country

🇩🇰 Denmark

Phone Number

45 70 22 22 44

Ascendis Pharma (ASND) Price Chart

Ascendis Pharma Overview: Key Details and Summary

Stock data	2023	Change
Price	$148.75	N/A
Market Cap	$8.37B	N/A
Shares Outstanding	56.29M	0.38%
Employees	797.00	N/A

Valuation	2023	Change
P/E Ratio	-17.40	N/A
P/S Ratio	28.24	N/A

Earnings	2023	Change
Revenue	$296.45M	N/A
Earnings	-$535.12M	N/A
EPS	-8.55	N/A
Earnings Yield	-0.0575	N/A
Gross Margin	0.8336	N/A
Operating Margin	-1.71	N/A
Net income margin	-1.81	N/A